MFSD2A potentiates gastric cancer response to anti‐PD‐1 immunotherapy by reprogramming the tumor microenvironment to activate T cell response

BACKGROUND: The efficacy of anti‐programmed cell death protein 1 (PD‐1) immunotherapy in various cancers, including gastric cancer (GC), needs to be potentiated by more effective targeting to enhance therapeutic efficacy or identifying accurate biomarkers to predict clinical responses. Here, we atte...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Bin, Wang, Chun‐Mei, Wu, Hao‐Xiang, Wang, Feng, Chai, Yang‐Yang, Hu, Ye, Wang, Bing‐Jing, Yu, Zhou, Xia, Rong‐Hua, Xu, Rui‐Hua, Cao, Xue‐Tao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10565382/
https://www.ncbi.nlm.nih.gov/pubmed/37539769
http://dx.doi.org/10.1002/cac2.12476

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10565382/
https://www.ncbi.nlm.nih.gov/pubmed/37539769
http://dx.doi.org/10.1002/cac2.12476

Ejemplares similares